Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MGUS
MCID: MNC006
MIFTS: 48

Monoclonal Gammopathy of Uncertain Significance (MGUS)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

About this section

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance 12 15
Monoclonal Gammopathy of Undetermined Significance 12 73 20 70 32
Mgus 12 20

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:7442
ICD10 32 D47.2
UMLS 70 C0026470
Sources

Summaries for Monoclonal Gammopathy of Uncertain Significance

About this section
GARD : 20 Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma ). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop. Those with stable levels of monoclonal protein typically do not require treatment.

MalaCards based summary : Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to lymphoplasmacytic lymphoma and waldenstroem's macroglobulinemia. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is SDC1 (Syndecan 1), and among its related pathways/superpathways are Measles and NF-kappaB Signaling. The drugs rituximab and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A blood protein disease that is characterized by the presence of an abnormal protein called monoclonal protein in the blood.

Wikipedia : 73 Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma... more...

Sources

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

About this section

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 450)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 31.7 SDC1 MYOM2 IGHV4-38-2 CD38 CD19 B2M
2 waldenstroem's macroglobulinemia 31.5 SDC1 MYOM2 MAG IGHV4-38-2 CD38 CD19
3 neuritis 31.0 TNF MAG LTA IL6
4 disease by infectious agent 31.0 TNF MIR126 LTA IL6 CFHR2
5 cellulitis 30.9 TNF MYOM2 IL6
6 meningoencephalitis 30.8 TNF IL6 B2M
7 spondylitis 30.8 TNF LTA IL6
8 fasciitis 30.8 TNF MYOM2 LTA IL6
9 toxic shock syndrome 30.8 TNF MYOM2 LTA IL6
10 arthropathy 30.8 TNF LTA IL6 B2M
11 spondyloarthropathy 1 30.7 TNF IL6 CFHR2
12 skin disease 30.7 TNF MIR19A MIR126 IL6 FGFR3 B2M
13 lymphoma, mucosa-associated lymphoid type 30.7 SDC1 IGHV4-38-2 CD19 B2M
14 amyloidosis 30.7 TNF MYOM2 IL6 B2M
15 extramedullary plasmacytoma 30.7 SDC1 MYOM2 IL6 CD38 B2M
16 solitary osseous plasmacytoma 30.6 SDC1 NCAM1 MYOM2 CD38 B2M
17 bone disease 30.5 TNF SDC1 LTA IL6 FGFR3 B2M
18 mantle cell lymphoma 30.5 TNF IL6 CD19 CCND3 B2M
19 immune deficiency disease 30.4 TNF MIR126 LTA IL6 CFHR2 CD38
20 plasmacytoma 30.3 NCAM1 IL6 CD38 B2M
21 demyelinating disease 30.3 TNF MIR126 MAG IL6
22 common variable immunodeficiency 30.3 TNF IL6 CD38 CD19
23 poems syndrome 30.3 TNF MYOM2 IL6
24 gamma heavy chain disease 30.3 SDC1 IGHV4-38-2 CD38
25 respiratory failure 30.3 TNF SDC1 MIR126 LTA IL6
26 heavy chain disease 30.2 MYOM2 IGHV4-38-2 CFHR2
27 chronic polyneuropathy 30.2 MYOM2 MAG
28 chickenpox 30.2 TNF IL6 CD19
29 post-transplant lymphoproliferative disease 30.2 TNF LTA IL6 B2M
30 systemic lupus erythematosus 30.2 TNF SDC1 LTA IL6 CFHR2 CD38
31 peripheral nervous system disease 30.2 TNF NCAM1 MYOM2 MIR126 MAG IL6
32 plasma cell neoplasm 30.1 SDC1 MYOM2 IL6 IGHV4-38-2 FGFR3 B2M
33 marginal zone b-cell lymphoma 30.1 SDC1 IGHV4-38-2 CD19
34 smoldering myeloma 29.8 TENT5C SDC1 NSD2 NCAM1 MYOM2 MAFB
35 leukemia, acute myeloid 29.8 TNF NCAM1 MIR126 IL6 IGHV4-38-2 CD38
36 myeloma, multiple 29.7 TNF TENT5C SDC1 NSD2 NCAM1 MYOM2
37 leukemia, acute lymphoblastic 29.7 NCAM1 MIR126 IGHV4-38-2 CD38 CD19 CCND3
38 diffuse large b-cell lymphoma 29.6 TNF SDC1 MIR126 IL6 CD38 CD19
39 plasma cell leukemia 29.5 SDC1 NCAM1 MIR19A MAF IL6 FGFR3
40 leukemia, chronic lymphocytic 29.5 TNF SDC1 NCAM1 MIR19A MIR126 LTA
41 lymphoma, non-hodgkin, familial 29.4 SDC1 NCAM1 MIR126 IL6 IGHV4-38-2 CD38
42 light chain deposition disease 11.5
43 macroglobulinemia, waldenstrom 1 11.1
44 proteinuria, chronic benign 10.6
45 external pathological resorption 10.5 TNF IL6
46 scorpion envenomation 10.5 TNF IL6
47 physiological polycythemia 10.5 TNF IL6
48 autoimmune disease 10.5
49 thrombophilia due to thrombin defect 10.5
50 body mass index quantitative trait locus 11 10.5

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:



Diseases related to Monoclonal Gammopathy of Uncertain Significance
Sources

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

About this section

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.15 B2M CCND3 CD19 CD38 FGFR3 IL6
2 immune system MP:0005387 10.13 B2M CCND3 CD19 CD38 FGFR3 IL6
3 integument MP:0010771 9.91 B2M CD19 FGFR3 IL6 MAF MYOM2
4 liver/biliary system MP:0005370 9.76 B2M CCND3 CD19 IL6 LTA MAF
5 neoplasm MP:0002006 9.5 B2M CCND3 CD19 FGFR3 IL6 SDC1
6 vision/eye MP:0005391 9.32 CCND3 CD19 FGFR3 IL6 LTA MAF
Sources

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

About this section

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 195)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
rituximab Approved Phase 3 174722-31-7 10201696
2
Dalteparin Approved Phase 3 9005-49-6
3
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
4
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
5
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
6
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
7
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
8
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
9
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Iron Approved Phase 3 7439-89-6 23925 29936
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
14
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
15 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
16 Antirheumatic Agents Phase 3
17 Antineoplastic Agents, Immunological Phase 3
18 Immunologic Factors Phase 3
19 Anticoagulants Phase 3
20 Fibrinolytic Agents Phase 3
21 Heparin, Low-Molecular-Weight Phase 3
22 Neurotransmitter Agents Phase 3
23 Narcotics Phase 3
24 Excitatory Amino Acid Antagonists Phase 3
25 Analgesics, Opioid Phase 3
26 Cola Phase 3
27 Epoetin alfa Phase 3 113427-24-0
28 Hematinics Phase 3
29 Dermatologic Agents Phase 3
30 Antifungal Agents Phase 3
31 Amebicides Phase 3
32 Antiparasitic Agents Phase 3
33 Liposomal amphotericin B Phase 3
34 Antiprotozoal Agents Phase 3
35 Psychotropic Drugs Phase 3
36 Antiemetics Phase 3
37 Antipsychotic Agents Phase 3
38 Anti-Anxiety Agents Phase 3
39 ferric gluconate Phase 3
40 Iron Supplement Phase 3
41 Anesthetics Phase 3
42 Anesthetics, Intravenous Phase 3
43 Anesthetics, General Phase 3
44 Liver Extracts Phase 3
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751
47
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
48
Lenograstim Approved, Investigational Phase 2 135968-09-1
49
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
50
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA) Withdrawn NCT02920190 Phase 4 Liraglutide
2 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
3 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
4 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
5 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
6 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
7 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
8 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
9 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
10 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
11 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
12 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
14 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
15 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
16 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
17 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
18 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
19 A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
20 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
21 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
22 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
23 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
24 Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma Completed NCT00099047 Phase 2 celecoxib;placebo
25 A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM) Completed NCT01237054 Phase 2 18-NaF PET;18-FDG PET/CT
26 Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In Recruiting NCT04439006 Phase 2 Ibrutinib
27 A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma Active, not recruiting NCT03236428 Phase 2 Daratumumab
28 Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study Not yet recruiting NCT04731844 Phase 2 Curcumin plus Piperine
29 A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance Not yet recruiting NCT04614558 Phase 2 Isatuximab
30 A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00588822 Phase 2
31 The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study Terminated NCT00942422 Phase 2
32 A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) Terminated NCT00665652 Phase 2 Lenalidomide
33 Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies Terminated NCT00899353 Phase 2
34 Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease Withdrawn NCT01571726 Phase 2 Fluciclatide
35 Phase I Trial of High Dose Chemotherapy Using Amifostine for In-Vivo Protection of GM-CSF Primed Progenitor Cells Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
36 A Phase I Clinical And Pharmacological Study Of Pyroxamide (NSC 696085) In Patients With Advanced Malignancies Completed NCT00042900 Phase 1 pyroxamide
37 A Phase I Trial of EMD 121974 in Patients With Advanced or Metastatic Cancer Completed NCT00004258 Phase 1 cilengitide
38 Phase I Trial of Interleukin-12 Followed by Interferon-Alpha Completed NCT00003451 Phase 1
39 A Phase I and Pharmacologic Study of the Proteasome Inhibitor PS-341 in Patients With Advanced Solid Tumors and B-cell Lymphoproliferative Disorders Completed NCT00006362 Phase 1 bortezomib
40 Phase I Study of T Cell Depleted (TCD) Partially Matched Related Donor (PMRD) Hematopoietic Stem Cell Transplantation for High Risk Hematologic Diseases Using Intense Pre and Post Transplant Immunosuppression and Megadose CD34 "Veto" Cells Completed NCT00004904 Phase 1 cladribine;cyclophosphamide;etoposide;methylprednisolone;tacrolimus
41 Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies Completed NCT00004232 Phase 1 cyclosporine;methylprednisolone;prednisone
42 A Phase I Study of Low Dose Continuous Infusion Topotecan in Combination With 5-Fluorouracil and Leucovorin for Advanced Malignancies Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
43 A Phase IA Trial of Combined Murine IgG Monoclonal Anti-Transferrin Receptor Antibodies E2.3 and A27.15 in Cancer Patients Completed NCT00003082 Phase 1
44 A Phase I Study of the Biologic and Clinical Effects of 5-AZA-2'Deoxycytidine (DAC) in Patients With Advanced Malignancies Completed NCT00002980 Phase 1 decitabine
45 A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Completed NCT01219010 Phase 1
46 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
47 Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy Recruiting NCT03820817 Phase 1 Rifaximin
48 A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
49 Phase I Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Patients With Refractory Hematologic Malignancies/Bone Marrow Disorders Terminated NCT00004058 Phase 1 tetradecanoylphorbol acetate
50 Large Scale Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From Monoclonal Gammopathy of Undetermined Significance (MGUS) and Indolent Myeloma (SMM). Unknown status NCT01079429

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Sources

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

About this section
Sources

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

About this section

MalaCards organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

40
Bone Marrow, Bone, T Cells, Endothelial, Myeloid, B Cells, Prostate
Sources

Publications for Monoclonal Gammopathy of Uncertain Significance

About this section

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 1984)
# Title Authors PMID Year
1
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review. 61
33416902 2021
2
Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience. 61
33647732 2021
3
Patient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS). 61
33503552 2021
4
Screening for M-proteinemia consisting of monoclonal gammopathy of undetermined significance and multiple myeloma for 30 years among atomic bomb survivors in Hiroshima. 61
33389658 2021
5
Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma. 61
33516787 2021
6
Monoclonal gammopathy of undetermined significance (MGUS) manifestation in CNS: a regular or chance occurrence? 61
33762271 2021
7
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. 61
32780894 2021
8
[Lung involvement of pyoderma gangrenosum: Diagnostic and therapeutic discussion based on a case report and a targeted literature review]. 61
33773848 2021
9
IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in Scleromyxedema. 61
33739037 2021
10
Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia. 61
33764527 2021
11
Progression from Monoclonal gammopathy of undetermined significance of the immunoglobulin M class (IgM-MGUS) to Waldenstrom Macroglobulinemia is associated with an alteration in lipid metabolism. 61
33690107 2021
12
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. 61
33767199 2021
13
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. 61
33095415 2021
14
Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. 61
33810169 2021
15
Gamma heavy chain disease associated with rheumatoid arthritis: a case report. 61
33726782 2021
16
Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma. 61
33749761 2021
17
Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. 61
32955183 2021
18
Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. 61
33295006 2021
19
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. 61
33709474 2021
20
Monoclonal and polyclonal immunoglobulin G deposits on tubular basement membranes of native and pretransplant kidneys: A retrospective study. 61
33783928 2021
21
Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens. 61
33669483 2021
22
Human myeloma cell- and plasma-derived extracellular vesicles contribute to functional regulation of stromal cells. 61
33580572 2021
23
Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia. 61
33718795 2021
24
Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects. 61
33360970 2021
25
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). 61
33563898 2021
26
Acquired von Willebrand syndrome in monoclonal gammopathy - A scoping review on hemostatic management. 61
33733035 2021
27
Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report. 61
33639890 2021
28
Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. 61
33634586 2021
29
Abnormal coagulation profiles in monoclonal gammopathy of undetermined significance: a case series. 61
33640160 2021
30
Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. 61
33619185 2021
31
The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy. 61
33277411 2021
32
miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition. 61
33609405 2021
33
Efficacy of plasmapheresis as treatment for bilateral hyperviscosity syndrome related retinopathy in multiple myeloma. 61
33601903 2021
34
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. 61
33392702 2021
35
Smoldering multiple myeloma 40 years later: a story of unintended disease. 61
33430658 2021
36
Monoclonal gammopathy of undetermined significance coexisting in patients undergoing kidney transplantation does not adversely influence post-graft clinical outcome. 61
33564434 2021
37
Ocular manifestation of giant cell arteritis vs AL-amyloidosis: similar presentations but different approaches. 61
32787554 2021
38
Continuous function of 80 primary renal allografts for 30-47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long-term successes. 61
33112428 2021
39
Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: Report of four patients. 61
33308940 2021
40
Diagnostic and Therapeutic Challenges (Monoclonal gammopathy of undetermined significance-related uveitis with recalcitrant macular edema). 61
33438898 2021
41
[Management of multirefractory immune thrombocytopenia]. 61
33334631 2021
42
Disseminated Cryptococcal Disease in a Patient With Monoclonal Gammopathy of Undetermined Significance and Polycythemia Vera: A Case Report and Review of the Literature. 61
33552776 2021
43
Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. 61
33404262 2021
44
Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. 61
33582053 2021
45
A case of immunotactoid glomerulopathy in a patient with monoclonal gammopathy of renal significance. 61
33552417 2021
46
Monoclonal Gammopathies of 'Neurological Significance': Paraproteinemic Neuropathies. 61
33397535 2021
47
Multiple myeloma. 61
33516340 2021
48
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. 61
33435306 2021
49
Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. 61
32478420 2021
50
Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment? 61
33531904 2021
Sources

Variations for Monoclonal Gammopathy of Uncertain Significance

About this section

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13350 1 1 125000000 Gain Monoclonal gammopathy of undetermined significance
2 16482 1 125000000 249250621 Gain Monoclonal gammopathy of undetermined significance
3 55476 11 53700000 135006516 Gain Monoclonal gammopathy of undetermined significance
4 76533 13 32200000 40100000 Deletion NBEA Monoclonal gammopathy of undetermined significance
5 82835 14 17600000 107349540 Loss Monoclonal gammopathy of undetermined significance
6 89754 15 19000000 102531392 Gain Monoclonal gammopathy of undetermined significance
7 124088 19 1 26500000 Gain Monoclonal gammopathy of undetermined significance
8 166137 3 1 91000000 Gain Monoclonal gammopathy of undetermined significance
9 214491 6 61000000 171115067 Loss Monoclonal gammopathy of undetermined significance
10 253951 9 49000000 141213431 Gain Monoclonal gammopathy of undetermined significance
Sources

Expression for Monoclonal Gammopathy of Uncertain Significance

About this section
Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.
Sources

Pathways for Monoclonal Gammopathy of Uncertain Significance

About this section

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Measles 36
Show member pathways
 12.64 TNF IL6 CD19 CCND3 B2M
2
NF-kappaB Signaling 4
12.35 TNF NCAM1 CD38 CD19 B2M
3
Human T-cell leukemia virus 1 infection 36
12 TNF LTA IL6 CCND3 B2M
4
Hematopoietic cell lineage 36
11.66 TNF IL6 CD38 CD19
5
Innate Lymphoid Cell Differentiation Pathways 64
11.6 TNF NCAM1 LTA
6
Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.6 SDC1 NCAM1 IL6 CD19
7
Th1 Differentiation Pathway 64
Show member pathways
 11.57 TNF LTA IL6
8
IgA-Producing B Cells in the Intestine 64
11.47 TNF LTA IL6
9
Malaria 36
11.33 TNF SDC1 IL6
10
Dendritic Cells Developmental Lineage Pathway 64
11.22 TNF NCAM1 IL6 CD38 CD19
11
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.16 TNF SDC1 NCAM1 IL6 CD38 CD19
12
IL-10 Pathway 63
11.12 TNF IL6 CCND3
13
Overview of nanoparticle effects 1
10.61 TNF IL6 CCND3
14
EV release from cardiac cells and their functional effects 1
10.45 TNF MIR126
Sources

GO Terms for Monoclonal Gammopathy of Uncertain Significance

About this section

Cellular components related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 TNF SDC1 NCAM1 FGFR3 CD38 B2M
2 external side of plasma membrane GO:0009897 9.1 TNF SDC1 NCAM1 IGHV4-38-2 CD19 B2M

Biological processes related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron projection development GO:0010977 9.69 MAG CD38 B2M
2 positive regulation of protein kinase B signaling GO:0051897 9.67 TNF MIR126 FGFR3 CD19
3 response to glucocorticoid GO:0051384 9.63 TNF SDC1 IL6
4 humoral immune response GO:0006959 9.58 TNF LTA IL6
5 positive regulation of neuroinflammatory response GO:0150078 9.52 TNF IL6
6 cellular response to nicotine GO:0071316 9.49 TNF B2M
7 negative regulation of lipid storage GO:0010888 9.48 TNF IL6
8 vascular endothelial growth factor production GO:0010573 9.43 TNF IL6
9 negative regulation of neurogenesis GO:0050768 9.33 TNF IL6 B2M
10 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.32 TNF LTA
11 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.26 TNF LTA
12 positive regulation of glial cell proliferation GO:0060252 9.13 TNF LTA IL6
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 8.92 TNF MIR19A IL6 FGFR3

Molecular functions related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.23 TNF SDC1 NCAM1 MAFB FGFR3 CFHR2
Sources

Sources for Monoclonal Gammopathy of Uncertain Significance

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....